Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development...
_Logo_May 2014_low res.png
Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections
February 25, 2020 07:00 ET | Allecra Therapeutics GmbH
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactamEXBLIFEP safety profile was comparable to...
_Logo_May 2014_low res.png
Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
September 03, 2019 07:00 ET | Allecra Therapeutics GmbH
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...